Zenas Biopharma, Inc.

Biotechnology • Healthcare • Waltham, MA, United States • ZBIO (NMS)

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Stock Performance (90 Days)

Data through Dec 24, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Zenas Prepares For INDIGO Phase 3 Readout—Reinstating Buy Rating (ZBIO) - Seeking Alpha

Seeking Alpha • Dec 15

Zenas BioPharma (NASDAQ:ZBIO) Shares Down 6.4% - Here's Why - MarketBeat

MarketBeat • Dec 29

Zenas BioPharma stock slides 5% today as biotech shares sag; Phase 3 INDIGO data in focus - ts2.tech

ts2.tech • Dec 30

Zenas BioPharma (ZBIO): Reassessing Valuation After Orelabrutinib’s Phase 2b Lupus Success and China Phase 3 Green Light - Yahoo Finance

Yahoo Finance • Dec 16

H.C. Wainwright reiterates Buy rating on Zenas Biopharma stock amid competitor setback - Investing.com

Investing.com • Dec 16

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Zenas BioPharma, Inc. had layoffs?

No layoff events have been recorded for Zenas BioPharma, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Zenas BioPharma, Inc. have?

Zenas BioPharma, Inc. has approximately 130 employees.

What industry is Zenas BioPharma, Inc. in?

Zenas BioPharma, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Zenas BioPharma, Inc. a publicly traded company?

Yes, Zenas BioPharma, Inc. is publicly traded under the ticker symbol ZBIO on the NMS. The company has a market capitalization of approximately $2.32 billion.

Where is Zenas BioPharma, Inc. headquartered?

Zenas BioPharma, Inc. is headquartered in Waltham, MA, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.